已收盘 11-20 16:00:00 美东时间
+2.460
+1.00%
Biogen reports two-year Phase 2 CELIA data showing diranersen slows clinical decline and cuts tau biomarkers in early Alzheimer's disease.
11-18 23:40
XBI and IBB lagged SPY and QQQ as two FDA decisions and fresh Alzheimer's and obesity-drug data put biotech ETFs in focus.
11-16 22:23
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-home-starting-dose-alzheimers-disease-treatment
07-14 02:23
Top Wall Street analysts changed their outlook on top names. Upgrade on NIO, COF, KEYS, BIIB, and AXP, see other ratings and consider buying BIIB.
07-13 19:07
Analyst raised sales estimates for Spinraza HD due to positive uptake. Biogen makes strides in key priorities. PT increased to $256.
06-29 23:27
Needham analyst Ami Fadia maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $255 to $256.
06-29 18:08
Records from June 8, 2026 indicate that Representative Maria Elvira Salazar of ...
06-09 23:15
Top Wall Street analysts upgraded Biogen Inc. and Cognizant Technology Solutions, see analyst ratings page for full changes and other stock views.
06-08 21:58
UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ:BIIB) today announced that The Lancet, a world-leading medical journal, has published the full results from the Phase 3 PHOENYCS GO clinical trial
06-01 16:40
Mr. Bonney brings more than three decades of leadership experience in the biopharmaceutical industry, including significant expertise in multiple sclerosis (MS) and broader central nervous system markets. Notably, during
05-19 18:32